Skip to main content
SpringerLink
Log in

Contraception in the Setting of Obesity and Bariatric Surgery

  • Chapter
  • First Online:
Contraception for the Medically Challenging Patient

  • 1062 Accesses

Abstract

Until recently, contraceptive research has generally excluded women over 130 % of ideal body weight. Given the dramatic increase in obesity worldwide, it has become a public health necessity to address the use and safety of contraception in obese women. Current research on contraceptive efficacy and safety in obese women is overall reassuring, and most contraceptives are given a category 1 rating (no restriction) for obesity by major regulatory agencies such as the World Health Organization. Likewise, women with a history of bariatric surgery are eligible for most methods of contraception without restriction. Like all women, obese women wishing to avoid pregnancy should be encouraged to use the best methods for preventing pregnancy, either long-acting reversible or permanent methods. Providers should feel reassured in offering obese women a range of contraceptive options, without expectation of increased side effects or weight gain. This chapter reviews data on the efficacy, pharmacokinetics, and safety of modern methods of contraception in obese women, and in women undergoing bariatric surgery. We also address the effect of these contraceptive methods on lipid profiles.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ogden C, Carroll M, Kit B, Flegal K. Prevalence of obesity in the United States, 2009–2010. National Center for Health Statistics. 2012;82:1–8.

    Google Scholar 

  2. Obesity and overweight [Internet]. World Health Organization [cited 2013 Mar 6]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html

  3. Prentice A. The emerging epidemic of obesity in developing countries. Int J Epidemiol. 2005;35(1):93–9.

    PubMed  Google Scholar 

  4. Vilos GA, Marks J, Tureanu V, Abu-Rafea B, Vilos AG. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol. 2011;18(1):75–80.

    PubMed  Google Scholar 

  5. Weiss JL, Malone FD, Emig D, Ball RH, Nyberg DA, Comstock CH, et al. Obesity, obstetric complications and cesarean delivery rate—a population-based screening study. Am J Obstet Gynecol. 2004;190(4):1091–7.

    PubMed  Google Scholar 

  6. Kominiarek M. Bariatric surgery and pregnancy. ACOG Pract Bull. 2009;105:1–9.

    Google Scholar 

  7. Olson G. Obesity and implications for future generations. Am J Obstet Gynecol. 2012;206(3):255–7.

    PubMed  Google Scholar 

  8. Phelan S. Pregnancy: a “teachable moment” for weight control and obesity prevention. Am J Obstet Gynecol. 2010;202(2):135.e1–8.

    PubMed Central  Google Scholar 

  9. Merhi ZO. Impact of bariatric surgery on female reproduction. Fertil Steril. 2009;92(5):1501–8.

    PubMed  Google Scholar 

  10. Paulen ME, Zapata LB, Cansino C, Curtis KM, Jamieson DJ. Contraceptive use among women with a history of bariatric surgery: a systematic review. Contraception. 2010;82(1):86–94.

    PubMed  Google Scholar 

  11. Gesink Law DC, Maclehose RF, Longnecker MP. Obesity and time to pregnancy. Hum Reprod. 2006;22(2):414–20.

    PubMed  Google Scholar 

  12. van der Steeg JW, Steures P, Eijkemans MJC, Habbema JDF, Hompes PGA, Burggraaff JM, et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. Hum Reprod. 2007;23(2):324–8.

    PubMed  Google Scholar 

  13. Bajos N, Wellings K, Laborde C, Moreau C, for the CSF Group. Sexuality and obesity, a gender perspective: results from French national random probability survey of sexual behaviours. BMJ. 2010;340:2573–3.

    Google Scholar 

  14. Kaneshiro B, Jensen JT, Carlson N, Harvey SM, Nichols M, Edelman A. Body mass index and sexual behavior. Obstet Gynecol. 2008;112(3):586–92.

    PubMed  Google Scholar 

  15. Shaw K, Edelman A. Obesity and oral contraceptives: a clinician’s guide. Best Pract Res Clin Endocrinol Metab. 2013;27(1):55–65.

    CAS  PubMed  Google Scholar 

  16. Hatcher R, Trussell J, Nelson AL, Cates W. Contraceptive technology. 20th ed. Decatur, GA: Bridging the Gap Foundation; 2011.

    Google Scholar 

  17. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol. 2012;120(1):21–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  18. Grimes DA, Shields WC. Family planning for obese women: challenges and opportunities. Contraception. 2005;72(1):1–4.

    PubMed  Google Scholar 

  19. Mirena Prescribing Information. United States Food and Drug Administration. 2013. p. 1–29.

    Google Scholar 

  20. Seeber B, Ziehr SC, Gschlieβer A, Moser C, Mattle V, Seger C, et al. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception. 2012;86(4):345–9.

    CAS  PubMed  Google Scholar 

  21. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. Acta Obst Gynecol Scand. 1999;78:716–21.

    CAS  Google Scholar 

  22. Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception. 2013;88(4):503–8.

    CAS  PubMed  Google Scholar 

  23. Ng YW, Liang S, Singh K. Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism—a randomized comparative study. Contraception. 2009;79(1):24–8.

    CAS  PubMed  Google Scholar 

  24. Kaunitz AM. Use of hormonal contraception in women with coexisting medical conditions. ACOG Pract Bull. 2006;73:1–20.

    Google Scholar 

  25. Hillman JB, Miller RJ, Inge TH. Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. J Women’s Health. 2011;20(4):533–8.

    Google Scholar 

  26. Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive disorders in women. Hum Reprod Update. 2003;9(4):359–72.

    PubMed  Google Scholar 

  27. Curtis KM, Marchbanks PA, Peterson HB. Neoplasia with use of intrauterine devices. Contraception. 2007;75(6):S60–9.

    PubMed  Google Scholar 

  28. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG IUS) in the treatment of endometrial hyperplasia—a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139(2):169–75.

    CAS  PubMed  Google Scholar 

  29. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasingintrauterine system for endometrial hyperplasia:a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203(6):547.e1–10.

    CAS  Google Scholar 

  30. Mody SK, Hacker MR, Dodge LE, Thornton K, Schneider B, Haider S. contraceptive counseling for women who undergo bariatric surgery. J Women’s Health. 2011;20(12):1785–8.

    Google Scholar 

  31. Merhi ZO. Challenging oral contraception after weight loss by bariatric surgery. Gynecol Obstet Invest. 2007;64(2):100–2.

    PubMed  Google Scholar 

  32. Darney PD, Patel A, Rosen K, Shapiro L, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009;91(5):1646–53.

    PubMed  Google Scholar 

  33. Hohmann HL, Creinin MD. The contraceptive implant. Clin Obstet Gynecol. 2007;50(4):907–17.

    PubMed  Google Scholar 

  34. Le J, Tsourounis C. Implanon: a critical review. Ann Pharmacother. 2001;35:329–36.

    CAS  PubMed  Google Scholar 

  35. Huber J. Pharmacokinetics of Implanon. Contraception. 1998;58:85S–90S.

    CAS  PubMed  Google Scholar 

  36. Makarainen L, van Beek A, Tuomivaara L, Asplund B, Bennick H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril. 1998;69(4):714–21.

    CAS  PubMed  Google Scholar 

  37. Mornar S, Chandra A, Mistretta S, Neustadt A, Martinez G, Gilliam M. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol. 2012;207(2):110.e1–6.

    CAS  Google Scholar 

  38. Diaz S, Pavez M, Moo-Young C, Bardin CW, Croxatto HB. Clinical trial with 3-keto-desogestrel subdermal implants. Contraception. 1991;44(4):393–408.

    CAS  PubMed  Google Scholar 

  39. Davies G, Feng LX, Newton JR. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception. 1993;47:251–61.

    CAS  PubMed  Google Scholar 

  40. Croxatto H, Urbancsek J, Massai MR, Bennick H, van Beek A. A multicentre efficacy and safety study of the singlecontraceptive implant Implanon. Hum Reprod. 1999;14(4):976–81.

    CAS  PubMed  Google Scholar 

  41. Biswas A, Viegas OAC, Roy AC. Effect of Implanon® and Norplant® subdermal contraceptive implants on serum lipids—a randomized comparative study. Contraception. 2003;68(3):189–93.

    CAS  PubMed  Google Scholar 

  42. Dilbaz B, Ozdegirmenci O, Caliskan E, Dilbaz S, Haberal A. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception. 2010;81(6):510–4.

    CAS  PubMed  Google Scholar 

  43. Guazzelli CAF, Barreiros FA, Barbosa R, de Araújo FF, Moron AF. Extended regimens of the vaginal contraceptive ring: cycle control. Contraception. 2009;80(5):430–5.

    PubMed  Google Scholar 

  44. Bender NM, Segall-Gutierrez P, Najera SOL, Stanczyk FZ, Montoro M, Mishell Jr DR. Effects of progestin-only long-acting contraception on metabolic markers in obese women. Contraception. 2013;88(3):418–25.

    CAS  PubMed  Google Scholar 

  45. Ciangura C, Corigliano N, Basdevant A, Mouly S, Declèves X, Touraine P, et al. Etonorgestrel concentrations in morbidly obese women following Roux-en-Y gastric bypass surgery: three case reports. Contraception. 2011;84(6):649–51.

    CAS  PubMed  Google Scholar 

  46. Chan LM, Westhoff CL. Tubal sterilization trends in the United States. Fertil Steril. 2010;94(1):1–6.

    PubMed  Google Scholar 

  47. Winner B, Peipert JF, Zhao Q, Buckel C, Madden TE, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.

    CAS  PubMed  Google Scholar 

  48. Peterson H, Trussell J, Hughes E, Taylor L. The risk of pregnancy after tubal sterilization: findings from the US Collaborative Review of Steriliation (CREST). Am J Obstet Gynecol. 1996;174(4):1161–9.

    CAS  PubMed  Google Scholar 

  49. Yan J, Hsu J, Yin C. Comparative study of Filshie clip and Pomeroy method for postpartum sterilization. Int J Gynecol Obstet. 1990;33:263–7.

    CAS  Google Scholar 

  50. Jamieson DJ, Hillis S, Duerr A, Marchbanks PA, Costello C, Peterson H. Complications of interval laparoscopic tubal sterilization: findings from the United States Collaborative Review of Sterilization. Obstet Gynecol. 2000;96(6):997–1002.

    CAS  PubMed  Google Scholar 

  51. Shabanzadeh DM, Sørensen LT. Laparoscopic surgery compared with open surgery decreases surgical site infection in obese patients. Ann Surg. 2012;256(6):934–45.

    PubMed  Google Scholar 

  52. Connor V. Essure: a review six years later. J Minim Invasive Gynecol. 2009;16(3):282–90.

    PubMed  Google Scholar 

  53. Anderson T, Yunker A, Scheib S, Callahan T. Hysteroscopic sterilization success in outpatient vs office setting is not affected by patient or procedural characteristics. J Minim Invasive Gynecol. 2013;20(6):858–63.

    PubMed  Google Scholar 

  54. Rodriguez MI, Seuc A, Sokal DC. Comparative efficacy of postpartum sterilisation with the titanium clip versus partial salpingectomy: a randomised controlled trial. BJOG. 2012;120(1):108–12.

    PubMed  Google Scholar 

  55. Oligbo N, Revicky V, Udeh R. Pomeroy technique or Filshie clips for postpartum sterilisation? Retrospective study on comparison between Pomeroy procedure and Filshie clips for a tubal occlusion at the time of Caesarean section. Arch Gynecol Obstet. 2009;281(6):1073–5.

    PubMed  Google Scholar 

  56. Krishnan S, Hacker M, Haider S, Thornton K, Trainor L, Lim R, et al. Contraceptive counseling and utilization in women who underwent bariatric surgery. Contraception. 2009;80(2):212.

    Google Scholar 

  57. Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.

    Google Scholar 

  58. Mosher WD, Martinez G, Chandra A, Abma J, Wilson SJ. Use of contraception and use of family planning services in the United States: 1982–2002. Center for Disease Control Advance Data. 2004;350:1–46.

    Google Scholar 

  59. Holt V, Cushing-Haugen K, Daling J. Body weight and risk of oral contraceptive failure. Obstet Gynecol. 2002;99(5):820–7.

    PubMed  Google Scholar 

  60. Dinger J, Do Minh T, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol. 2011;117(1):33–40.

    CAS  PubMed  Google Scholar 

  61. McNicholas C, Zhao Q, Secura G, Allsworth JE, Madden T, Peipert JF. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol. 2013;121(3):585–92.

    PubMed Central  PubMed  Google Scholar 

  62. Westhoff CL, Torgal AH, Mayeda ER, Stanczyk FZ, Lerner J, Benn E, et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use. Obstet Gynecol. 2010;116(2):275–83.

    PubMed  Google Scholar 

  63. McLaren L. Socioeconomic status and obesity. Epidemiol Rev. 2007;29(1):29–48.

    PubMed  Google Scholar 

  64. Westhoff CL, Torgal AT, Mayeda ER, Shimoni N, Stanczyk FZ, Pike MC. Predictors of noncompliance in an oral contraceptive clinical trial. Contraception. 2012;85(5):465–9.

    PubMed  Google Scholar 

  65. Westhoff C, Reape K, Shu H. Impact of body weight on observed pregnancy rates with a low-dose estrogen, 91-day extended regimen oral contraceptive. Contraception. 2009;80(2):196–7.

    Google Scholar 

  66. Edelman AB, Carlson NE, Cherala G, Munar MY, Stouffer RL, Cameron JL, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic. Contraception. 2009;80(2):119–27.

    CAS  PubMed Central  PubMed  Google Scholar 

  67. Trussell J, Schwarz EB, Guthrie K. Obesity and oral contraceptive pill failure. Contraception. 2009;79(5):334–8.

    PubMed Central  PubMed  Google Scholar 

  68. Westhoff C. Higher body weight does not affect NuvaRing’s efficacy (abstract). Obstet Gynecol. 2005;105(4S):56S.

    Google Scholar 

  69. Zieman M, Guillebaud J, Weisberg E, Shangold G, Fisher AC, Creasy G. Contraceptive efficacy and cycle control with the Ortho Evra™/Evra™ transdermal system: the analysis of pooled data. Fertil Steril. 2002;77(2):S13–8.

    PubMed  Google Scholar 

  70. Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception. 2010;82(4):314–23.

    CAS  PubMed  Google Scholar 

  71. Edelman AB, Cherala G, Munar MY, DuBois B, McInnis M, Stanczyk FZ, et al. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. Contraception. 2013;87(2):220–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  72. Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception. 2010;81(6):474–80.

    CAS  PubMed Central  PubMed  Google Scholar 

  73. Westhoff CL, Torgal AH, Mayeda ER, Petrie K, Thomas T, Dragoman M, et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. Am J Obstet Gynecol. 2012;207(1):39.e1–6.

    CAS  Google Scholar 

  74. Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, et al. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception. 2007;75(6):430–7.

    CAS  PubMed  Google Scholar 

  75. Goebelmann U, Mashchak CA, Mishell Jr D. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol. 1985;151(7):868–77.

    Google Scholar 

  76. Blickstein I. Thrombophilia and women’s health: an overview. Obstet Gynecol Clin North Am. 2006;33(3):347–56.

    PubMed  Google Scholar 

  77. Trussell J, Guthrie KA, Schwarz EB. Much ado about little: obesity, combined hormonal contraceptive use and venous thrombosis. Contraception. 2008;77(3):143–6.

    CAS  PubMed  Google Scholar 

  78. Liston F, Davies GAL. Thromboembolism in the obese pregnant woman. Seminars in Perinatology. 2011;35(6):330–4.

    PubMed  Google Scholar 

  79. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Center for Disease Control Morbidity and Mortality Weekly Report. 2010 May 26;59:1–88.

    Google Scholar 

  80. Rad M, Kluft C, Menard J, Burggraaf J, de Kam ML, Meijer P, et al. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. Am J Obstet Gynecol. 2006;195(1):72–7.

    CAS  PubMed  Google Scholar 

  81. Jensen JT, Burke AE, Barnhart KT, Tillotson C, Messerle-Forbes M, Peters D. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception. 2008;78(6):451–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  82. Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol. Contraception. 2007;76(1):4–7.

    CAS  PubMed  Google Scholar 

  83. Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013;87(1):93–100.

    CAS  PubMed  Google Scholar 

  84. Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception. 2010;81(5):408–13.

    CAS  PubMed  Google Scholar 

  85. Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care. 2000;5(4):265–74.

    CAS  PubMed  Google Scholar 

  86. Gallo MF, Lopez LM, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight (review). Cochrane Database Syst Rev. 2012:1–116.

    Google Scholar 

  87. Edelman A, Jensen JT, Bulechowsky M, Cameron J. Combined oral contraceptives and body weight: do oral contraceptives cause weight gain? A primate model. Hum Reprod. 2011;26(2):330–6.

    CAS  PubMed  Google Scholar 

  88. O’Connell KJ, Osborne LM, Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. Contraception. 2005;72(5):323–7.

    PubMed  Google Scholar 

  89. Mohamed AMM, El-Sherbiny WSM, Mostafa WAI. Combined contraceptive ring versus combined oral contraceptive (30 mcg ethinyl estradiol and 3-mg drospirenone). Int J Gynecol Obstet. 2011;114(2):145–8.

    CAS  Google Scholar 

  90. Sibai B, Odlind V, Meador M, Shangold G, Fisher AC, Creasy G. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra™/Evra™). Fertil Steril. 2002;77(2):S19–26.

    PubMed  Google Scholar 

  91. Beasley A, Estes C, Guerrero J, Westhoff C. The effect of obesity and low-dose oral contraceptives on carbohydrate and lipid metabolism. Contraception. 2012;85(5):446–52.

    CAS  PubMed  Google Scholar 

  92. Tuppurainen M, Klimscheffskij R, Venhola M, Dieben TOM. The combined contraceptive vaginal ring (NuvaRing®) and lipid metabolism: a comparative study. Contraception. 2004;69(5):389–94.

    CAS  PubMed  Google Scholar 

  93. Elkind-Hirsch KE, Darensbourg C, Ogden B, Ogden LF, Hindelang P. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception. 2007;76(5):348–56.

    CAS  PubMed  Google Scholar 

  94. Victor A, Odlind V, Kral JG. Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass. Gastroenterol Clin North Am. 1987;16(3):483–91.

    CAS  PubMed  Google Scholar 

  95. Gerrits E, Ceulemans R, van Hee R, Hendrickz L, Totte E. Contraceptive treatment after biliopancreatic diversion needs consensus. Obes Surg. 2003;13:378–82.

    PubMed  Google Scholar 

  96. Segall-Gutierrez P, Taylor D, Liu X, Stanzcyk F, Azen S, Mishell Jr DR. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception. 2010;81(6):487–95.

    CAS  PubMed  Google Scholar 

  97. Mishell Jr D. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1996;51(S5):381–90.

    Google Scholar 

  98. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70(4):269–75.

    CAS  PubMed  Google Scholar 

  99. Fotherby K, Koetsawang S. Metabolism of injectable formulations of contraceptive steroids in obese and thin women. Contraception. 1982;26(1):51–8.

    CAS  PubMed  Google Scholar 

  100. Smit J, Botha J, McFadyen L, Beksinska M. Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval. Contraception. 2004;69(1):3–7.

    CAS  PubMed  Google Scholar 

  101. Lopez LM. Grimes DA, Chen M, Otterness C et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2013; 4. Art No. CD008452. doi: 10.1002/14651858.CD008452.pub3.

  102. Curtis KM, Ravi A, Gaffield ML. Progestogen-only contraceptive use in obese women. Contraception. 2009;80(4):346–54.

    CAS  PubMed  Google Scholar 

  103. Westhoff C, Jain JK, Milsom I, Ray A. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception. 2007;75(4):261–7.

    CAS  PubMed  Google Scholar 

  104. Bonny AE, Secic M, Cromer B. A longitudinal comparison of body composition changes in adolescent girls receiving hormonal contraception. J Adolesc Health. 2009;45(4):423–5.

    PubMed Central  PubMed  Google Scholar 

  105. Bonny AE, Secic M, Cromer B. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate. Obstet Gynecol. 2011;117(4):793–7.

    PubMed Central  PubMed  Google Scholar 

  106. Gerlach LS, Saldaña SN, Wang Y, Nick TG, Spigarelli MG. Retrospective review of the relationship between weight change and demographic factors following initial depot medroxyprogesterone acetate injection in adolescents. Clin Therap. 2011;33(2):182–7.

    CAS  Google Scholar 

  107. Segall-Gutierrez P, Xiang AH, Watanabe RM, Trigo E, Stanczyk FZ, Liu X, et al. Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use. Contraception. 2012;85(1):36–41.

    CAS  PubMed  Google Scholar 

  108. Berenson A, Rahman M, Wilkenson G. Effect of injectable and oral contraceptives on serum lipids. Obstet Gynecol. 2009;114(4):786–94.

    CAS  PubMed Central  PubMed  Google Scholar 

  109. Grimes DA, von Hertzen H, Piaggio G, Van Lock P. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet. 1998;352:428–33.

    CAS  Google Scholar 

  110. Croxatto HB, Brache V, Pavez M, Cochon L, Forcelledo ML, Alvarez F, et al. Pituitary–ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. Contraception. 2004;70(6):442–50.

    CAS  PubMed  Google Scholar 

  111. Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375(9714):555–62.

    CAS  PubMed  Google Scholar 

  112. Moreau C, Trussell J. Results from pooled Phase III studies of ulipristal acetate for emergency contraception. Contraception. 2012;86(6):673–80.

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, et al. Progesterone receptor modulator for emergency contraception. Obstet Gynecol. 2006;108(5):1089–97.

    CAS  PubMed Central  PubMed  Google Scholar 

  114. Glasier A, Cameron ST, Blithe D, Scherrer B, Mathe H, Levy D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84(4):363–7.

    CAS  PubMed  Google Scholar 

  115. Turok DK, Godfrey EM, Wojdyla D, Dermish A, Torres L, Wu SC. Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle. Hum Reprod. 2013;28(10):2672–6.

    CAS  PubMed  Google Scholar 

  116. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod. 2012;27(7):1994–2000.

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA

    Katharine Simmons M.D. & Alison Edelman M.D., M.P.H.

Authors
  1. Katharine Simmons M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alison Edelman M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alison Edelman M.D., M.P.H. .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA

    Rebecca H. Allen

  2. Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA

    Carrie A. Cwiak

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Simmons, K., Edelman, A. (2014). Contraception in the Setting of Obesity and Bariatric Surgery. In: Allen, R., Cwiak, C. (eds) Contraception for the Medically Challenging Patient. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1233-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1233-9_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1232-2

  • Online ISBN: 978-1-4939-1233-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation